PUBLISHED FOR OPPOSITION
on 19 Nov 2024
Last Applicant/ Owned by
40-20 Techno 6-ro, Yuseong-gu
Daejeon
KR
34014
Serial Number
90357299 filed on 03rd Dec 2020
Registration Number
N/A
Correspondent Address
Jae Youn Kim
Filing Basis
1. intent to use
Disclaimer
NO DATA
EXO-TARGET
Biotechnology research; technological research in the field of cell biology; laboratory research in the field of cell biology; pharmaceutical drug development services; genetic testing for scientific research purposes; research in the field of chemistry; drug discovery services; medical research and development services; pharmaceutical research and development services; biopharmaceutical research Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Biotechnology research; technological research in the field of cell biology; laboratory research in the field of cell biology; pharmaceutical drug development services; genetic testing for scientific research purposes; research in the field of chemistry; drug discovery services; medical research and development services; pharmaceutical research and development services; biopharmaceutical research and development services
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Pharmaceutical preparations for treating cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemico-pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; drug delivery agents in the form of capsules, tablets, pills, powders, liquids, suspensions, injection, creams, emulsions, gels, liniments, lotions, ointments, pathes, solutions, syrups, aerosols, granules, implants, inhalants, pellets that facilitate the delivery of pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biological preparations in the nature of comprising extracellular vesicles known as exosomes for therapeutic applications; extracellular vesicles for pharmaceutical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biochemical drug delivery agent in the form of capsules, tablets, pills, powders, liquids, suspensions, injection, creams, emulsions, gels, liniments, lotions, ointments, pathes, solutions, syrups, aerosols, granules, implants, inhalants, pellets that facilitate the delivery of pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; nutraceutical preparations for therapeutic or medical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemical preparations for pharmaceutical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemical preparations for medical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; preparations of microorganisms for medical and veterinary use for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; reagents for use in medical genetic testing; diagnostic reagents for medical use; biological preparations for medical or veterinary purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biological reagents for clinical medical use
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [001]
Chemical Products
Biological preparations, other than for medical or veterinary purposes; biological tissue cultures, other than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; biological preparation for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of cosmetics; protein for use in the manufacture of cosmetics; proteins for the food industry; chemical reagents, other than for medical or veterinary purpose
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 90357299
Mark Type
No Service Mark
Attorney Docket Number
No TK0172069
44D Filed
Yes
44D Current
No
44E filed
Yes
44E Current
Yes
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 19th Nov 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 19th Nov 2024 | PUBLISHED FOR OPPOSITION |
| 13th Nov 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 11th Oct 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 07th Oct 2024 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| 07th Oct 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 07th Oct 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 08th Jul 2024 | FINAL REFUSAL E-MAILED |
| 08th Jul 2024 | FINAL REFUSAL WRITTEN |
| 08th Jul 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |